Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022
-Parsippany, NJ – May 11, 2022 – Ferring Pharmaceuticals today announced they will present data from analyses of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI) after antibiotic treatment, as part of Digestive Disease Week (DDW 2022). The congress will take place in San Diego, CA, and virtually from May 21 – 24, 2022. […]
-
Data for Ferring’s RBX2660 Published in BMC Infectious Diseases: “Durable Reduction of Clostridioides difficile Infection Recurrence and Microbiome Restoration after Treatment with RBX2660: Results from an Open-Label Phase 2 Clinical Trial”
-Primary objective was to compare treatment success of RBX2660 to historical control group A key secondary outcome was the safety profile of RBX2660 through 24 months after treatment Post hoc analysis indicated that 91% of evaluable responders remained CDI occurrence-free to 24 months after treatment Parsippany, NJ, USA – March 15, 2022 – Ferring Pharmaceuticals today announced that BioMed Central […]
-
Ferring Announces Investment in Robyn, an Online Community that Provides Access to Fertility and Parental Wellness Resources
-Ferring Pharmaceuticals has finalized a two-year investment agreement including an acquisition option with Robyn. Together, Ferring and Robyn will provide expanded resources for people on their path to parenthood. The investment in Robyn reflects Ferring’s strategy to partner with innovative start-ups focused on supporting people during their family-building journeys. Parsippany, NJ– February 15, 2022 – Underscoring its commitment to empowering […]